Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jieling Miao

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Health and Quality of Life Outcomes|August 24, 2019
A comparison of nurses' and physicians' perception of cancer treatment burden based on reported adverse eventsShing M Lee, Jieling Miao, Ruby Wu, et al.
Cancer|November 8, 2017
Estimating global treatment toxicity burden from adverse-event dataShing M Lee, Dawn L Hershman, Jieling Miao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2022
Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI-Treated Patients with EGFR-Mutant NSCLC (SWOG S1403)Philip C Mack, Jieling Miao, Mary W Redman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2019
Circulating Tumor Cell Clusters in Patients with Metastatic Breast Cancer: a SWOG S0500 Translational Medicine StudyCostanza Paoletti, Jieling Miao, Emily M Dolce, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 15, 2020
Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307)Darya A Kizub, Jieling Miao, Mark M Schubert, et al.
Clinical Lung Cancer|August 13, 2017
Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 TrialsHoward L West, James Moon, Antoinette J Wozniak, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 15, 2019
SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)Martin J Edelman, Mary W Redman, Kathy S Albain, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2019
SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)Corey J Langer, Mary W Redman, James L Wade, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2019
Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905)Anne S Tsao, Jieling Miao, Ignacio I Wistuba, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 14, 2019
SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)Charu Aggarwal, Mary W Redman, Primo N Lara, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Health and Quality of Life Outcomes|August 24, 2019
A comparison of nurses' and physicians' perception of cancer treatment burden based on reported adverse eventsShing M Lee, Jieling Miao, Ruby Wu, et al.
Cancer|November 8, 2017
Estimating global treatment toxicity burden from adverse-event dataShing M Lee, Dawn L Hershman, Jieling Miao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2022
Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI-Treated Patients with EGFR-Mutant NSCLC (SWOG S1403)Philip C Mack, Jieling Miao, Mary W Redman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2019
Circulating Tumor Cell Clusters in Patients with Metastatic Breast Cancer: a SWOG S0500 Translational Medicine StudyCostanza Paoletti, Jieling Miao, Emily M Dolce, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 15, 2020
Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307)Darya A Kizub, Jieling Miao, Mark M Schubert, et al.
Clinical Lung Cancer|August 13, 2017
Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 TrialsHoward L West, James Moon, Antoinette J Wozniak, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 15, 2019
SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)Martin J Edelman, Mary W Redman, Kathy S Albain, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2019
SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)Corey J Langer, Mary W Redman, James L Wade, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2019
Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905)Anne S Tsao, Jieling Miao, Ignacio I Wistuba, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 14, 2019
SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)Charu Aggarwal, Mary W Redman, Primo N Lara, et al.
Pageof 3